Section Arrow
Quote
ALDX.NASDAQ
- Aldeyra Therapeutics
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 6.26
-0.04 (-0.63%)
Day High 
6.59 
Prev. Close
6.3 
1-M High
7.2 
Volume 
1.44M 
Bid
6.29
Ask
6.45
Day Low
6.2 
Open
6.31 
1-M Low
4.78 
Market Cap 
376.16M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 6.62 
20-SMA 6.46 
50-SMA 6 
52-W High 7.2 
52-W Low 3.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.94/-0.53
Enterprise Value
391.16M
Balance Sheet
Book Value Per Share
1.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.